H&H國際控股(01112.HK)就發行5820.7萬美元票據訂立購買協議
格隆匯6月14日丨H&H國際控股(01112.HK)發佈公吿,2023年6月13日,公司與初步買方就發行5820.7萬美元於2026年到期的13.5%票據訂立購買協議。
根據是次發售換取現金而提呈發售的新票據(交換票據除外)的所得款項淨額將約為5400萬美元。公司擬使用新票據(包括透過提交要約)的所得款項淨額償還2024年票據及其應計利息,倘若與僅若新票據的發行規模大於2024年票據的未償還金額,剩餘所得款項淨額將償還優先融資項下的部分未償還債務。新票據將僅遵照S規例在美國境外以機構發售提呈發售及出售。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.